NVCR
NovoCure Ltd

7,822
Mkt Cap
$1.54B
Volume
1.92M
52W High
$21.55
52W Low
$9.82
PE Ratio
-11.06
NVCR Fundamentals
Price
$13.30
Prev Close
$13.52
Open
$12.88
50D MA
$12.74
Beta
1.42
Avg. Volume
3.37M
EPS (Annual)
-$1.22
P/B
4.47
Rev/Employee
$408,319.63
$1,232.17
Loading...
Loading...
News
all
press releases
NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know
Explore NovoCure's (NVCR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Novocure Announces Optune Lua Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that Japans Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua through the countrys National Health Insurance coverage. Optune Lua is...
Business Wire·1d ago
News Placeholder
Equities Analysts Set Expectations for NovoCure Q1 Earnings
NovoCure Limited (NASDAQ:NVCR - Free Report) - Equities researchers at HC Wainwright raised their Q1 2026 earnings per share estimates for NovoCure in a note issued to investors on Thursday, February...
MarketBeat·2d ago
News Placeholder
Hohimer Wealth Management LLC Takes Position in NovoCure Limited $NVCR
Hohimer Wealth Management LLC purchased a new position in NovoCure Limited (NASDAQ:NVCR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The...
MarketBeat·3d ago
News Placeholder
Novocure to Participate in 2026 Leerink Global Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph...
Business Wire·4d ago
News Placeholder
NovoCure (NASDAQ:NVCR) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS
NovoCure (NASDAQ:NVCR - Get Free Report) announced its earnings results on Thursday. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus...
MarketBeat·5d ago
News Placeholder
NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
read more...
Benzinga·5d ago
News Placeholder
HC Wainwright Increases NovoCure (NASDAQ:NVCR) Price Target to $49.00
HC Wainwright upped their price target on shares of NovoCure from $47.00 to $49.00 and gave the company a "buy" rating in a report on Thursday...
MarketBeat·5d ago
News Placeholder
NovoCure (NVCR) Q4 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·5d ago
News Placeholder
NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of +46.01% and +0.83%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
<
1
2
...
>

Latest NVCR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.